With growing mechanistic evidence of clonal shifts, a complex interplay of BCL-2 family proteins, metabolic reprogramming or tumor microenvironment in B-cell malignancies, future studies should continue to define biomarkers that could predict the response of venetoclax. The gene discussed is BCL2; the disease is neoplasm.